How does inflammation cause Barrett's metaplasia?

Current Opinion in Pharmacology

Volumn 9, Issue 6, 2009, Pages 721-726

  Colleypriest, Benjamin J ^a   Ward, Stephen G ^a   Tosh, David ^a  

^a University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CYCLOOXYGENASE 2; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; TRANSCRIPTION FACTOR CDX2; TUMOR NECROSIS FACTOR ALPHA;

BARRETT METAPLASIA; BILE REFLUX; CANCER INCIDENCE; CARCINOGENESIS; DISEASE MODEL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMAN; METAPLASIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INDUCTION; REVIEW; RISK FACTOR; SQUAMOUS EPITHELIUM; SYMPTOM; TH1 CELL; TH2 CELL;

ADENOCARCINOMA; ANIMALS; BARRETT ESOPHAGUS; CYCLOOXYGENASE 2; CYTOKINES; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; HUMANS; METAPLASIA; MODELS, IMMUNOLOGICAL; NF-KAPPA B; PRECANCEROUS CONDITIONS;

EID: 70449502829     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.09.005     Document Type: Review

References (53)

1. Quinlan J.M., Colleypriest B.J., Farrant M., and Tosh D. Epithelial metaplasia and the development of cancer. Biochim Biophys Acta 1776 (2007) 10-21
2. Slack J.M. Stem cells in epithelial tissues. Science (New York, NY) 287 (2000) 1431-1433
3. Pohl H., and Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97 (2005) 142-146
4. Bollschweiler E., Wolfgarten E., Gutschow C., and Holscher A.H. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92 (2001) 549-555
5. Brown L.M., Devesa S.S., and Chow W.H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 100 (2008) 1184-1187. The authors have collated epidemiological data from 1975 to 2005. These data demonstrate the continuing dramatic rise in incidence of oesophageal adenocarcinoma.
6. Chandrasoma P., Wickramasinghe K., Ma Y., and DeMeester T. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia?. Dis Esophagus 20 (2007) 36-41
7. Chandrasoma P. Controversies of the cardiac mucosa and Barrett's oesophagus. Histopathology 46 (2005) 361-373
8. Wang K.K., and Sampliner R.E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 103 (2008) 788-797
9. Takubo K., Aida J., Naomoto Y., Sawabe M., Arai T., Shiraishi H., Matsuura M., Ell C., May A., Pech O., et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol 40 (2009) 65-74
10. Liu W., Hahn H., Odze R.D., and Goyal R.K. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol 104 (2009) 816-824
11. Playford R.J. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 55 (2006) 442
12. van Soest E.M., Dieleman J.P., Siersema P.D., Sturkenboom M.C., and Kuipers E.J. Increasing incidence of Barrett's oesophagus in the general population. Gut 54 (2005) 1062-1066
13. Vaezi M.F., and Richter J.E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 111 (1996) 1192-1199
14. Jankowski J.A., Harrison R.F., Perry I., Balkwill F., and Tselepis C. Barrett's metaplasia. Lancet 356 (2000) 2079-2085
15. Lagergren J., Bergstrom R., Lindgren A., and Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
16. Falk G.W. Barrett's esophagus. Gastroenterology 122 (2002) 1569-1591
17. Fitzgerald R.C., Onwuegbusi B.A., Bajaj-Elliott M., Saeed I.T., Burnham W.R., and Farthing M.J. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50 (2002) 451-459
18. Fitzgerald R.C., Abdalla S., Onwuegbusi B.A., Sirieix P., Saeed I.T., Burnham W.R., and Farthing M.J. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 51 (2002) 316-322
19. O'Riordan J.M., Abdel-latif M.M., Ravi N., McNamara D., Byrne P.J., McDonald G.S., Keeling P.W., Kelleher D., and Reynolds J.V. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 100 (2005) 1257-1264
20. Moons L.M., Kusters J.G., Bultman E., Kuipers E.J., van Dekken H., Tra W.M., Kleinjan A., Kwekkeboom J., van Vliet A.H., and Siersema P.D. Barrett's oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol 207 (2005) 269-276
21. Dvorakova K., Payne C.M., Ramsey L., Holubec H., Sampliner R., Dominguez J., Dvorak B., Bernstein H., Bernstein C., Prasad A., et al. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res 10 (2004) 2020-2028
22. Dvorak K., Chavarria M., Payne C.M., Ramsey L., Crowley-Weber C., Dvorakova B., Dvorak B., Bernstein H., Holubec H., Sampliner R.E., et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to Barrett's esophagus. Clin Cancer Res 13 (2007) 5305-5313
23. Dannenberg A.J., Altorki N.K., Boyle J.O., Dang C., Howe L.R., Weksler B.B., and Subbaramaiah K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2 (2001) 544-551
24. Hamoui N., Peters J.H., Schneider S., Uchida K., Yang D., Vallböhmer D., Hagen J.A., DeMeester S.R., DeMeester T.R., Danenberg K., et al. Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. Arch Surg 139 (2004) 712-716 discussion 716-717
25. Morris C.D., Armstrong G.R., Bigley G., Green H., and Attwood S.E. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96 (2001) 990-996
26. Ferguson H.R., Wild C.P., Anderson L.A., Murphy S.J., Johnston B.T., Murray L.J., Watson R.G., McGuigan J., Reynolds J.V., and Hardie L.J. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 17 (2008) 727-731. This publication demonstrates the important of the Cyclooxygenase enzyme, Cox2. The authors carried out a case control study and showed an increased risk for oesophageal adenocarcinoma with a single nucleotide polymorphism (8473 T → C) in the COX-2 gene.
27. Zhang X., Miao X., Tan W., Ning B., Liu Z., Hong Y., Song W., Guo Y., Zhang X., Shen Y., et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129 (2005) 565-576
28. Moons L.M., Kuipers E.J., Rygiel A.M., Groothuismink A.Z., Geldof H., Bode W.A., Krishnadath K.K., Bergman J.J., van Vliet A.H., Siersema P.D., et al. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol 102 (2007) 2373-2379. The authors provide the first demonstration that single nucleotide polymorphisms in the COX-2 gene promoter region (-765C and -1195A), (which increase COX-2 expression), were associated with an increased risk of oesophageal adenocarcinoma.
29. Whiteman D.C., Webb P.M., Green A.C., Hayward N.K., Parsons P.G., Purdie D.M., Smithers B.M., Gotley D., Clouston A., Brown I., et al. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 17 (2008) 1169-1178
30. Duan L., Wu A.H., Sullivan-Halley J., and Bernstein L. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev 17 (2008) 126-134
31. Oyama K., Fujimura T., Ninomiya I., Miyashita T., Kinami S., Fushida S., and Ohta T. Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide. Nippon Shokakibyo Gakkai Zasshi 104 (2007) 1183-1191
32. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., and Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
33. Souza R.F., Krishnan K., and Spechler S.J. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol 295 (2008) G211-218
34. Mutoh H., Sakurai S., Satoh K., Osawa H., Hakamata Y., Takeuchi T., and Sugano K. Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut 53 (2004) 1416-1423
35. Silberg D.G., Sullivan J., Kang E., Swain G.P., Moffett J., Sund N.J., Sackett S.D., and Kaestner K.H. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 122 (2002) 689-696
36. Kazumori H., Ishihara S., and Kinoshita Y. Roles of caudal-related homeobox gene Cdx1 in oesophageal epithelial cells in Barrett's epithelium development. Gut 58 (2009) 620-628. This significant publication provides, for the first time, evidence of the induction of CDX1 in oesophagitis before the development of intestinal metaplasia in a rat model of Barrett's metaplasia. The authors also examined the interplay between CDX1 and CDX2 and demonstrated that CDX1 and CDX2 cause upregulation of each other by directly binding to the promoter of the other transcription factor.
37. Wong N.A., Wilding J., Bartlett S., Liu Y., Warren B.F., Piris J., Maynard N., Marshall R., and Bodmer W.F. CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci U S A 102 (2005) 7565-7570
38. Moons L.M., Bax D.A., Kuipers E.J., Van Dekken H., Haringsma J., Van Vliet A.H., Siersema P.D., and Kusters J.G. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 57 (2004) 1063-1068
39. Stairs D.B., Nakagawa H., Klein-Szanto A., Mitchell S.D., Silberg D.G., Tobias J.W., Lynch J.P., and Rustgi A.K. Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus. PLoS ONE 3 (2008) e3534. This is a highly novel study in immortalised human oesophageal keratinocytes, demonstrating that CDX1 in concert with c-myc causes induction of intestinal cytokeratins and mucins similar to the phenotype seen in Barrett's metaplasia.
40. Ericsson A., Kotarsky K., Svensson M., Sigvardsson M., and Agace W. Functional characterization of the CCL25 promoter in small intestinal epithelial cells suggests a regulatory role for caudal-related homeobox (Cdx) transcription factors. J Immunol 176 (2006) 3642-3651
41. Kazumori H., Ishihara S., Rumi M.A., Kadowaki Y., and Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 55 (2006) 16-25
42. Wu J., Gong J., Geng J., and Song Y. Deoxycholic acid induces the overexpression of intestinal mucin, MUC2, via NF-kB signaling pathway in human esophageal adenocarcinoma cells. BMC Cancer 8 (2008) 333
43. Kim S., Domon-Dell C., Wang Q., Chung D.H., Di Cristofano A., Pandolfi P.P., Freund J.N., and Evers B.M. PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology 123 (2002) 1163-1178
44. Ikeda H., Sasaki M., Ishikawa A., Sato Y., Harada K., Zen Y., Kazumori H., and Nakanuma Y. Interaction of Toll-like receptors with bacterial components induces expression of CDX2 and MUC2 in rat biliary epithelium in vivo and in culture. Lab Invest 87 (2007) 559-571. This publicatoin examines the effects of pathogen associated molecular patterns (PAMPs) on Cdx2 expression, providing the first evidence that bacterial products, such as lipopolysaccharides cause induction of Cdx2 and mucin 2 in biliary epithelial cells via toll-like receptors.
45. Ikeda H., Sasaki M., Ohira S., Ishikawa A., Sato Y., Harada K., Zen Y., and Nakanuma Y. Tumor necrosis factor-alpha induces the aberrant expression of mucus core protein-2 in non-neoplastic biliary epithelial cells via the upregulation of CDX2 in chronic cholangitis. Hepatol Res 38 (2008) 1006-1017. This publication provides the first demonstration that IL-1β, IL-6, IFNγ and TNFα induce Cdx2 mRNA in biliary epithelial cells.
46. O'Neill L.A., and Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7 (2007) 353-364
47. Chang C.L., Lao-Sirieix P., Save V., De La Cueva Mendez G., Laskey R., and Fitzgerald R.C. Retinoic acid-induced glandular differentiation of the oesophagus. Gut 56 (2007) 906-917. This publication provides the first demonstration that IL-1β, IL-6, IFNγ and TNFα induce Cdx2 mRNA in biliary epithelial cells.
48. Li J.D., Feng W., Gallup M., Kim J.H., Gum J., Kim Y., and Basbaum C. Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells. Proc Natl Acad Sci U S A 95 (1998) 5718-5723
49. Li J., Johnson X.D., Iazvovskaia S., Tan A., Lin A., and Hershenson M.B. Signaling intermediates required for NF-kappa B activation and IL-8 expression in CF bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 284 (2003) L307-315
50. Kim Y.D., Kwon E.J., Park D.W., Song S.Y., Yoon S.K., and Baek S.H. Interleukin-1beta induces MUC2 and MUC5AC synthesis through cyclooxygenase-2 in NCI-H292 cells. Mol Pharmacol 62 (2002) 1112-1118
51. Hussain S.P., and Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121 (2007) 2373-2380
52. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., and Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
53. Harris R.E., Beebe-Donk J., Doss H., and Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13 (2005) 559-583